Medical Devices
Electrophysiology is one of the fastest growing segments of cardiovascular medicine. Negotiation for purchase of this technology requires a deep understanding of how these systems can be highly configurable, and how components can be priced and discounted differently.
There have been many ideas proposed as solutions for reducing costly hospital readmissions, but one concept that hasn't gotten much attention over the years is patient empowerment.
Although there's little hardcore evidence to date that mobile health technology will dramatically reduce U.S. healthcare costs, several thought leaders are optimistic.
The delivery of coronary artery stents is a procedure that affects over 1 million patients each year in the United States. With an aging population, the declining cost of stents and reimbursement tracking with the consumer price index, the market for stenting continues to grow.
The market will continue to grow, but slowly, while international demand looks promising.
Purchasers can often achieve better deals on cardiac rhythm management devices with bulk purchases, system purchases, and market share agreements. But before committing to a bulk purchase, it's important to ensure that your volume warrants such an agreement.
Much attention has focused on the "patent cliff" faced by pharmaceutical companies. There is another patent cliff approaching that has not yet received much attention -- the end of patent protection for many minimally invasive surgery devices.
If mHealth entrepreneurs and investors want to take the burgeoning industry to the next level, they're going to have to change their focus, said experts kicking off the 2013 mHealth Summit.
With venture capital firms investing record amounts in the healthcare space, mobile health entrepreneurs are keen to take advantage. As a result, next month's mHealth Summit Venture+ Forum may be the place to see many deals go down.
Medical device maker Stryker Corp. will pay $13.3 million to the Securities and Exchange Commission to settle civil charges that the company bribed physicians, healthcare professionals and government officials to obtain or keep business in five countries.